halcinonide / Generic mfg. - LARVOL DELTA

Synthesis of O-Prenylated O-Glycosylated and O-Benzylated Phenazines Derivatives and Their Antimicrobial and Molecular Docking Studies. (PubMed, Chem Biodivers) - "Specifically, compounds 4e, 6e, and 7e exhibited considerable antibacterial activity, inhibiting zones of up to 12 mm, whereas compounds 4c, 4d, 6e, and 7c possessed moderate antifungal activity (12-13 mm), compared to fluconazole (23 mm). Structure-activity relationship analysis proposes the integration of halog substituents and glycosylation leads to increased potency by increasing lipophilicity and interacting better with membranes. Molecular docking studies also confirmed these findings, revealing suitable binding affinities of the active compounds with microbial target proteins. Overall, this work offers new phenazine scaffolds potential candidates for the development of antibacterial and antifungal drugs."

Journal

Cu-Fe bimetallic nanozyme@halloysite-sodium alginate composite hydrogels for the treatment of atopic dermatitis. (PubMed, Biomater Sci) - "Through the mouse dermatitis model, it was seen that a CuO-Fe3O4@HNTs-SA composite hydrogel has a good therapeutic effect on atopic dermatitis. Compared with the positive drug halcinonide solution, the CuO-Fe3O4 nanozyme-incorporated hydrogel showed an enhanced therapeutic effect, which shows promising prospects for the clinical treatment of atopic dermatitis."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis. (PubMed, Front Genet) - "Additionally, leveraging the Connectivity Map (CMAP) database allowed us to predict six potential pharmacological agents-halcinonide, lomitapide, TG-101348, GSK-690693, loteprednol, and indacaterol-that might serve as therapeutic interventions for SIM. This research advances our understanding of the molecular basis of SIM, presenting new diagnostic biomarkers and potential drug targets. Further studies with larger clinical datasets are warranted to validate these findings and explore the therapeutic potential of the identified drugs."

Journal • Infectious Disease • Inflammation • Myositis • Septic Shock • CXCL10 • IL6 • STAT1

Halcinonide activates smoothened to ameliorate ischemic stroke injury. (PubMed, Life Sci) - "This study identified a new target and a candidate chemical for therapy of ischemic stroke, hopefully reducing its morbidity and mortality."

IO biomarker • Journal • Cardiovascular • CNS Disorders • Ischemic stroke • BCL2 • IL6 • SMO • TNFA

Single-Atom Catalysts with Isolated Cu1-N4 Sites for Atopic Dermatitis Cascade Catalytic Therapy via Activating PPAR Signaling. (PubMed, Small) - "In vivo experiments show that Cu1-N4 ISACs are more potent than a recommended typical medicine (halcinonide solution). Additionally, RNA sequencing and bioinformatic analysis reveal that Cu1-N4 ISACs reduce inflammation and inhibit ROS production by activating PPAR signaling, which is aberrantly reduced in AD. Therefore, the synthesized catalytic medicine offers an alternative to alleviate AD and has the potential to serve as PPAR agonists for treating similar diseases."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Exposure to synthetic steroid hormones and precocious puberty in girls: A case-control study. (PubMed, Ecotoxicol Environ Saf) - "Prednisolone (0.31), fluorometholone acetate (0.24), and dexamethasone acetate (0.12) had the highest weight. In conclusion, precocious puberty was associated with halcinonide and budesonide exposure, but not steroid hormone mixture among girls. It highlighted the management of the residual synthetic steroid hormones in the environment and provided a direction for the prevention of precocious puberty."

Journal • Pediatrics

Dual-Site Biomimetic Cu/Zn-MOF for Atopic Dermatitis Catalytic Therapy via Suppressing FcγR-Mediated Phagocytosis. (PubMed, J Am Chem Soc) - "Animal experiments show that Cu/Zn-MOF outperforms halcinonide solution (a potent steroid medication) in terms of preventing mechanical injuries, reducing cutaneous water loss, and inhibiting inflammatory responses while presenting favorable biosafety. Mechanistically, Cu/Zn-MOF functions through an FcγR-mediated phagocytosis signal pathway, decreasing the continuous accumulation of ROS in AD and ultimately suppressing disease progression. These findings will provide an effective paradigm for AD therapy and contribute to the development of two-site bionics (TSB)."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Identification and structural characterization of major stress degradation products of halcinonide by liquid chromatography-high-resolution mass spectrometry. (PubMed, Biomed Chromatogr) - "The chromatographic method that was developed has been validated in compliance with the Q2(R1) guideline of the International Council for Harmonization. ProTox-II was used to perform in silico toxicity studies in order to evaluate the toxicity potential of both halcinonide and the identified degradation products."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Topical halcinonide may benefit patients with psoriasis with inadequate biologics response (Healio) - "'For patients lacking an adequate response to biologics alone, combinations of biologic therapy with other psoriasis treatments can be used for improvement,' Jerry Bagel, MD, MS...and colleagues wrote."

Media quote

Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis. (PubMed, J Drugs Dermatol) - "Tildrakizumab plus topical halcinonide ointment is safe and effective in controlling psoriasis for patients inadequately responding to tildrakizumab monotherapy.Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766-772. doi:10.36849/JDD.6830."

Combination therapy • Journal • Dermatology • Immunology • Psoriasis

Therapeutic effects and mechanisms of Ku-Gan formula on atopic dermatitis: A pilot clinical study and modular pharmacology analysis with animal validation. (PubMed, J Ethnopharmacol) - "These results showed that KG is a safe and effective topical treatment for AD with low recurrence. In addition, our study identified potential molecular pathways and therapeutic candidate targets of the KG formula, providing evidence for its clinical applicability in AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL17A • IL1B • IL6 • STAT3 • TIMP1 • TRAF3IP2 • TRAF6

A Novel Approach to Assess the Potency of Topical Corticosteroids. (PubMed, Pharmaceutics) - "The potencies of clobetasol propionate, halcinonide, mometasone furoate, and fluocinolone acetonide were compared using the resulting E data following the fitting of the relevant response data to the E model where mometasone furoate > fluocinolone acetonide = clobetasol propionate > halcinonide. This ranking lists the respective inherent potencies of the APIs, which will facilitate the choice of a suitable candidate for incorporation into an appropriate topical corticosteroid product for a specific clinical indication."

Journal

A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. (PubMed, Infect Genet Evol) - "The results suggest the effectiveness of lansoprazole, folic acid, sulfamonomethoxine, tolnaftate, diclofenamide, halcinonide, saquinavir, metronidazole, ebselen, lidocaine and benzocaine, histone deacetylase (HDAC) inhibitors, heat shock protein 90 (HSP90) inhibitors, and many other clinically approved drugs as potent drugs against COVID-19 outbreak. Making new drugs remain a lengthy process, so the drug repurposing approach provides an insight into the therapeutics that might be helpful in this pandemic. In this study, pathway enrichment and protein network analysis are also performed, and the effectiveness of some drugs obtained from the CMap analysis has been investigated according to previous researches."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • HSP90AA1

Indian court temporarily stalls Sun Pharma’s Ranbaxy deal (Bloomberg.com) - "An Indian court temporarily stalled Sun Pharmaceutical Industries Ltd. (SUNP)’s $3.2 billion purchase of Ranbaxy Laboratories Ltd. (RBXY) as it considers a petition alleging insider trading....Admitting a writ petition filed by a group of investors seeking a probe by the Securities and Exchange Board of India into any insider trading in Ranbaxy shares,...In the deal announced on April 7, the companies said Ranbaxy investors will get 0.8 share in Sun for every one of their shares, or about 457 rupees."

Anticipated M & A • Corporate lawsuit • Psoriasis

Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers (clinicaltrials.gov) - P=N/A; N=208; Recruiting; Sponsor: Assistance Publique Hopitaux De Marseille; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar

Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep (clinicaltrials.gov) - P=N/A; N=20; Completed; Sponsor: Massachusetts General Hospital; Active, not recruiting -> Completed ; N=30 -> 20 ; Trial primary completion date: Jul 2014 ->Jul 2013

Enrollment change • Trial completion • Trial primary completion date • Biosimilar • Immunology

Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation. (PubMed) - PLoS One - "These data indicate Clobetasol and Halcinonide as potential promyelinating drugs and also provide a mechanistic understanding of their mode of action in the pathway leading to myelination in OPCs. Furthermore, our classification of glucocorticoids with respect to MBP expression provides important novel insights into their effects in the CNS and a rational criteria for their choice in combinatorial therapies in de-myelinating diseases."

Journal • Biosimilar

Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study. (PubMed) - "Halcinonide and fluocinonide were extracted from the strips and concentrations were measured using liquid chromatography-mass spectrometry. Results demonstrated the immediate absorption of fluocinonide and halcinonide into the stratum corneum within 1 hour of application followed by a sustained release of halcinonide and a steady decline of fluocinonide after peaking."

Journal • Biosimilar • Inflammation

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. (clinicaltrials.gov) - P4; N=25; Recruiting; Sponsor: Psoriasis Treatment Center of Central New Jersey

Clinical • Combination therapy • New P4 trial • Dermatology • Dermatopathology • Immunology • Psoriasis